Skip to main content
. 2022 Apr 12;10(4):e004527. doi: 10.1136/jitc-2022-004527

Figure 2.

Figure 2

Phenotypic and molecular characterization of lung cancer stem cells (CSC). (A) Flow cytometry profiles of CD34, CD44, PECAM-1 (CD31), CD24, CD166, C-X-C chemokine receptor type 4 (CXCR4), vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) in IGR-Heu, Heu-CSC, CSC-1 and CSC-2. Percentages of positive cells and mean immunofluorescence intensity (MFI) (in parentheses) are shown. (B) Western blot analysis of NANOG, SNAIL1 and SOX2 proteins in IGR-Heu and CSC. Right, normalization of proteins relative to F-actin. (C) Western blot analysis of total GSK-3β and phospho-GSK-3β proteins in IGR-Heu, Heu-CSC, CSC-1 and CSC-2. Right, ratio of phospho-GSK-3β to total GSK-3β. Data are from one representative experiment out of three. (D) Flow cytometry profiles of major histocompatibility complex class I (MHC-I) and HLA-A2 on IGR-Heu, Heu-CSC, CSC-1 and CSC-2. Percentage of positive cells and MFI (in parentheses) are included. (E) Flow cytometry analyses of E-cadherin and intercellular adhesion molecule (ICAM)-1 expression on IGR-Heu, Heu-CSC, CSC-1 and CSC-2. Percentage of positive cells and MFI are shown.